Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Original Research

Yasuo Inoue¹  Junji Chiba¹  Akiko Yabuki¹  Katsuaki Kanbe¹  Masashi Taguchi¹ 

[1] Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan.;

关键词: golimumab;    IL-6;    rheumatoid arthritis;    TNF-α;   

DOI  :  10.4137/CMAMD.S22155

 received in 2014-11-26, accepted in 2015-01-08,  发布年份 2015

来源: Sage Journals

【 摘 要 】

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metalloproteinase (MMP)-3, TNF-α, and IL–6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab.

【 授权许可】

CC BY-NC   
© 2015 SAGE Publications.

【 图 表 】

Figure 11.

Figure 7.

Figure 10.

Figure 4

Figure 6.

Figure 2

Figure 1